JP2025000628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025000628A5 JP2025000628A5 JP2024151952A JP2024151952A JP2025000628A5 JP 2025000628 A5 JP2025000628 A5 JP 2025000628A5 JP 2024151952 A JP2024151952 A JP 2024151952A JP 2024151952 A JP2024151952 A JP 2024151952A JP 2025000628 A5 JP2025000628 A5 JP 2025000628A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- domain
- nkp46
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 62
- 229920001184 polypeptide Polymers 0.000 claims 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims 60
- 108090000623 proteins and genes Proteins 0.000 claims 44
- 102000004169 proteins and genes Human genes 0.000 claims 44
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 6
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 6
- 102000050738 human NCR1 Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000053350 human FCGR3B Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101150019418 IGHV4-30-4 gene Proteins 0.000 claims 1
- 101150050798 IGKV1-39 gene Proteins 0.000 claims 1
- 101000589304 Macaca fascicularis Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000025171 antigen binding proteins Human genes 0.000 claims 1
- 108091000831 antigen binding proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271474P | 2015-12-28 | 2015-12-28 | |
| US62/271,474 | 2015-12-28 | ||
| PCT/EP2016/081953 WO2017114694A1 (en) | 2015-12-28 | 2016-12-20 | VARIABLE REGIONS FOR NKp46 BINDING PROTEINS |
| JP2018552124A JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2022096649A JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096649A Division JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025000628A JP2025000628A (ja) | 2025-01-07 |
| JP2025000628A5 true JP2025000628A5 (enExample) | 2025-04-14 |
Family
ID=57796296
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552124A Active JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2022096649A Active JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2024151952A Pending JP2025000628A (ja) | 2015-12-28 | 2024-09-04 | ＮＫｐ４６結合タンパク質の可変領域 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552124A Active JP7091250B2 (ja) | 2015-12-28 | 2016-12-20 | ＮＫｐ４６結合タンパク質の可変領域 |
| JP2022096649A Active JP7551693B2 (ja) | 2015-12-28 | 2022-06-15 | ＮＫｐ４６結合タンパク質の可変領域 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11001629B2 (enExample) |
| EP (1) | EP3397645B1 (enExample) |
| JP (3) | JP7091250B2 (enExample) |
| CN (2) | CN115925933A (enExample) |
| AU (1) | AU2016383475B2 (enExample) |
| CA (1) | CA3007898A1 (enExample) |
| WO (1) | WO2017114694A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| US9767555B2 (en) * | 2015-01-05 | 2017-09-19 | Case Western Reserve University | Disease characterization from fused pathology and radiology data |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| EP3397645B1 (en) | 2015-12-28 | 2026-03-25 | Innate Pharma | Variable regions for nkp46 binding proteins |
| FR3061716B1 (fr) * | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
| CN110300765B (zh) | 2017-01-24 | 2024-08-23 | 依奈特制药公司 | Nkp46结合剂 |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| EP3713959A1 (en) | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CA3099308A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| CN110540590B (zh) | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制物的开发和应用 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| JP2022525703A (ja) * | 2019-03-20 | 2022-05-18 | ジャベリン・オンコロジー・インコーポレイテッド | 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法 |
| BR112022017924A2 (pt) | 2020-03-10 | 2022-12-20 | Massachusetts Inst Technology | Composições e métodos para imunoterapia de câncer npm1c-positivo |
| US20230183342A1 (en) * | 2020-04-06 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN113637074B (zh) * | 2020-05-11 | 2024-09-24 | 上海怀越生物科技有限公司 | NKp46抗体及其制备方法和应用 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202216174A (zh) * | 2020-06-30 | 2022-05-01 | 日商蓋亞生物製藥有限公司 | 使ｎｋ細胞與抗體之結合穩定化之方法及其利用 |
| CN112029001B (zh) * | 2020-09-02 | 2022-09-06 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| TWI905354B (zh) * | 2020-12-31 | 2025-11-21 | 法商英耐特醫藥公司 | 結合至NKp46及CD123之多功能自然殺手 (NK) 細胞接合體 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| KR20230154235A (ko) * | 2021-03-05 | 2023-11-07 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | NKp46에 대한 항체 및 이의 적용 |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| KR20240019786A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| JP2024524301A (ja) * | 2021-07-02 | 2024-07-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用 |
| CN115611984A (zh) * | 2021-07-16 | 2023-01-17 | 上海怀越生物科技有限公司 | NKp46抗体及其制备方法和应用 |
| JP2024534838A (ja) * | 2021-08-30 | 2024-09-26 | インヒブルクス インコーポレイテッド | ＮＫｐ４６結合ポリペプチド及びその使用 |
| US20250230246A1 (en) * | 2021-10-27 | 2025-07-17 | Samyang Biopharm Usa Inc. | Anti-mic antibodies with variant fc domains |
| US20250051440A1 (en) | 2021-12-14 | 2025-02-13 | Institut National de la Santé et de la Recherche Médicale | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| WO2023143341A1 (en) * | 2022-01-25 | 2023-08-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric nkp46 |
| KR20250017240A (ko) | 2022-05-27 | 2025-02-04 | 사노피 | FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자 |
| CN116003595B (zh) * | 2022-07-11 | 2024-02-02 | 南方医科大学第三附属医院（广东省骨科研究院） | 靶向nk细胞nkp46受体的纳米抗体及其制备方法和应用 |
| CN119768434A (zh) * | 2022-08-19 | 2025-04-04 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗体及其应用 |
| CN116003627B (zh) * | 2022-09-16 | 2025-05-13 | 四川大学华西医院 | NKG2D-NKp46细胞接合器分子及其用途 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2024224313A1 (en) | 2023-04-24 | 2024-10-31 | Sanofi | Use of cd123 nk cell engager for treating aml and related disorders |
| CN121399268A (zh) * | 2023-06-14 | 2026-01-23 | 上海北恒生物科技有限公司 | 工程化的滋养细胞及其用途 |
| US20250064935A1 (en) | 2023-07-13 | 2025-02-27 | Sanofi | Natural killer cells and cd123 nk cell engager combination therapy |
| US20250195653A1 (en) | 2023-11-28 | 2025-06-19 | Sanofi | Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders |
| CN117442721B (zh) * | 2023-12-20 | 2024-03-15 | 苏州艾凯利元生物科技有限公司 | 一种包括nk细胞和nk细胞接合器分子的组合物 |
| WO2026055280A1 (en) | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2288307C (en) * | 1999-11-15 | 2012-05-15 | Universita Di Genova | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| EP1575615A1 (en) * | 2002-12-23 | 2005-09-21 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| WO2005000086A2 (en) * | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
| US20070178106A1 (en) * | 2004-04-30 | 2007-08-02 | Innate Pharma, S.A. | Compositions and methods for enhancing nk cell activity |
| CN101300272B (zh) * | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| US8426565B2 (en) * | 2007-08-30 | 2013-04-23 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| CN102770456B (zh) * | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US20140234342A1 (en) * | 2011-06-21 | 2014-08-21 | Innate Pharma | Nkp46-mediated nk cell tuning |
| ES2747920T3 (es) * | 2013-02-14 | 2020-03-12 | Innate Pharma | Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL) |
| WO2015015489A1 (en) * | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
| CN106456749B (zh) * | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
| JP6822849B2 (ja) * | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| AU2016284871B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| EP3397645B1 (en) | 2015-12-28 | 2026-03-25 | Innate Pharma | Variable regions for nkp46 binding proteins |
| CN110300765B (zh) | 2017-01-24 | 2024-08-23 | 依奈特制药公司 | Nkp46结合剂 |
-
2016
- 2016-12-20 EP EP16826025.5A patent/EP3397645B1/en active Active
- 2016-12-20 JP JP2018552124A patent/JP7091250B2/ja active Active
- 2016-12-20 AU AU2016383475A patent/AU2016383475B2/en active Active
- 2016-12-20 WO PCT/EP2016/081953 patent/WO2017114694A1/en not_active Ceased
- 2016-12-20 CN CN202210862118.XA patent/CN115925933A/zh active Pending
- 2016-12-20 US US16/066,688 patent/US11001629B2/en active Active
- 2016-12-20 CN CN201680082632.4A patent/CN108779175B/zh active Active
- 2016-12-20 CA CA3007898A patent/CA3007898A1/en active Pending
-
2021
- 2021-05-10 US US17/315,547 patent/US11891444B2/en active Active
-
2022
- 2022-06-15 JP JP2022096649A patent/JP7551693B2/ja active Active
-
2024
- 2024-02-05 US US18/432,126 patent/US20240174748A1/en active Pending
- 2024-09-04 JP JP2024151952A patent/JP2025000628A/ja active Pending